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the indication for cytogenetic referral (e.g., initial diagnosis versus follow-up studies, pre-versus posttransplant studies, and lymphoid versus myeloid malignancies) and the clinical application of the cytogenetic results (e.g., selection of therapy). 6.1.5 Molecular genetics analyses are essential for diagnosis of some hematological neoplasms, and several molecular mutations, not detectable by cytogenetic analyses, provide important diagnostic and prognostic information. These are outside the scope of the current guidelines.
6.1.6 For quality assurance, the laboratory should monitor the numbers and types of hematological neoplasms received, percentage of cases with abnormal results, cell culture success rate, success rate of FISH and CMA studies, TAT, and correlation of FISH and CMA data with G-banded chromosome analysis results.
SPECIMEN COLLECTION AND PROCESSING

Specimen collection
6.2.1.1 Only those cells involved in the neoplastic process will harbor the abnormalities being sought. Therefore, the specimen type and culture techniques utilized should optimize the probability of detecting an abnormal clone.
6.2.1.2 In most cases, bone marrow is the tissue of choice for cytogenetic analyses of suspected hematological neoplasms. In some circumstances, alternative specimens may be used, including the following:
a. Peripheral blood specimens may yield informative results when the circulating blast cell percentage is higher than 10%. In general, the abnormal clone can be identified in such specimens, albeit not as often as in bone marrow. Peripheral blood or bone marrow can be used in chronic lymphocytic leukemia (CLL). b. Bone marrow core biopsy specimens. c. Bone marrow smears and core biopsy touch imprints can be used for interphase FISH. d. Lymph node biopsy material or biopsy material from a suspected lymphoid mass are the preferred tissue in all lymphomas. e. Cerebrospinal fluid. f. Extramedullary leukemia (myeloid sarcoma, chloroma) tissue biopsy.
6.2.1.3 Specimens should be collected under sterile conditions in sodium heparin tubes for chromosome and/or FISH analyses. Bone marrow aspirate and biopsy specimens should preferably be collected in an appropriate transport medium tube with sodium heparin. The concentration of sodium heparin should be ~20 U/ml of specimen (per either bone marrow volume alone or per total volume of bone marrow and transport medium combined). EDTA tubes can be used for procedures that require genomic DNA extraction.
6.2.1.4 The volume of bone marrow available will differ for adults and children. An approximate specimen of 1 to 3 ml should be requested. During specimen procurement, several draws are likely to be withdrawn. Because the first draw is more concentrated with neoplastic immature bone marrow cells, it is recommended that cytogenetics receive the first or second draw whenever possible.
6.2.1.5 Specimens should be received by the laboratory as soon as possible, ideally within 24 hours. Also, it is recommended that specimens be maintained at ambient temperature during transit. Extreme temperatures should be avoided.
6.2.1.6 If the specimen size precludes cell culture and conventional G-banded chromosome analysis, bone marrow smears or core biopsy touch imprints can be used for interphase FISH analysis. e. Well-differentiated T-cell disorders (e.g., T-cell leukemias, T-cell lymphoma, Sézary syndrome, and mycosis fungoides): T-cell mitogens may be helpful.
ANALYSIS
6.3.1 Conventional G-banded chromosome analysis 6.3.1.1 Cell selection: metaphase cells should not be selected for analysis solely on the basis of good chromosome morphology. In general, the technologist should select an area of the slide to begin the analysis and then examine metaphase cells as they appear consecutively in the microscope field, only skipping cells for which extremely poor morphology precludes chromosome identification. This technique can also be performed using automated metaphase finders by examining metaphase cells consecutively captured by the system. Sufficient cells should be analyzed or examined to maximize the detection of an abnormal clone and establish the clonality of the abnormality found. For each abnormal clone identified, clonal cells with the best chromosome morphology should be analyzed, captured, and karyotyped to provide the most accurate breakpoint assignment.
When cells are skipped because of poor morphology, it is important to attempt to count the number of chromosomes. This is particularly true for possible hyperdiploid or hypodiploid pediatric ALL and hyperdiploid plasma cell dyscrasias. In addition, attempts should be made to identify possible structural chromosomal abnormalities, particularly if the disease under consideration is associated with a specific recurring abnormality (e.g., the t(9;22) in chronic myeloid leukemia (CML)).
6.3.1.2 Number of cells evaluated: The number of metaphase cells analyzed versus the number of cells counted or scored should be appropriate for the type of the study (e.g., initial diagnosis or follow-up studies) and the purpose of the study (e.g., detection of residual disease or response to therapy, monitoring for clonal evolution, or monitoring of allogeneic transplant engraftment). For studies aimed solely at determining engraftment status, molecular methods and/or interphase FISH (in the case of opposite sex transplant) are more sensitive than G-banded chromosome analysis and are the preferred methodologies. Therefore, in consultation with the referring physician, cancellation of test ACMG StAndArdS And GuidelineS requests for G-banded chromosome analysis for engraftment status should be considered.
During the course of the cytogenetic analysis, it will become evident whether there is chimerism for donor and recipient cells. It is expected that there will be different approaches used by different laboratories to address these studies.
• 6 .3.3.1 CMA analysis can add valuable information that will support and supplement both G-banded chromosome analysis and FISH. It can detect small cryptic clinically significant copy number changes (CNCs) in various hematological neoplasms. Additionally, CMA SNP platforms can also detect copy-neutral loss of heterozygosity (cnLOH). However, this technology cannot detect balanced chromosomal rearrangements.
6.3.3.2 The clinical utility of genome-wide CMAs in cancer diagnostics is growing rapidly. This technology is being used to better identify high-risk patients and predict clinical outcomes. In view of the rapid introduction of CMAs into clinical practice, it is important that laboratories stay up-to-date with this technology.
6.3.3.3 Analysis and documentation of CMA studies should be in accordance with Section E11 of these standards and guidelines for clinical genetics laboratories.
Recommended cytogenetic analysis scheme in hematological neoplasms
Acute leukemias
Bone marrow is the preferred specimen for acute leukemias, but peripheral blood can be used when >10% circulating blast cells are present. 8 Interphase FISH analysis performed on bone marrow smears or core biopsy touch imprints is an alternative in cases with a dry tap and/or hemodiluted bone marrow aspirate and absent/low circulating blast cells. A strong collaboration with the oncologist and pathologist is important for should be performed first. Interphase FISH analysis is optional and could include the following probes: a. BCR-ABL1 fusion probes: for BCR-ABL1 fusion and ABL1 amplification b. KMT2A (MLL) rearrangement probes -In ALL, CMA analysis can be very helpful for detecting cryptic CNCs, with proven relevance to diagnosis, prognosis, and therapeutic response. [14] [15] [16] Examples include deletions involving PAX5 and IKZF1 genes. It can also help clarify the structure of complex chromosomal rearrangements. Finally, CMA SNP platforms can detect whole-chromosome cnLOH due to "doubling" of a near-haploid or low hypodiploid clone, which manifests in the form of a hyperdiploid or near-triploid karyotype. The prognosis of these two entities is very different.
Myelodysplastic syndromes
-Bone marrow is the preferred specimen for MDS. 17 Interphase FISH analysis performed on bone marrow smears or core biopsy touch imprints is an alternative in cases with a dry tap and/or hemodiluted bone marrow aspirate. A strong collaboration with the oncologist and pathologist is important in MDS cases, where other nonneoplastic hematological disorders can have a similar presentation. -G-banded chromosome analysis should preferably be performed first. In case of an incomplete/unsuccessful chromosome analysis or if the laboratory is unable to maintain a short TAT for chromosome analysis, the following probes can be bundled in an MDS FISH panel, 18 which should be performed on the diagnostic specimen: a. -5/5q-probes b. -7/7q-probes c. Centromeric probe for chromosome 8: for trisomy 8 d. 20q-probe -Recent data suggest that MDS exhibits abundant clonal CNCs and cnLOH, often in the setting of a normal metaphase karyotype and with no previously identified clonal markers. CMA analysis is proving to be very useful in uncovering these genomic aberrations in MDS. 19, 20 Examples include cryptic 5q deletions distal to the EGR1 gene (5q31). These can be missed by G-banded chromosome and FISH analyses. 21 
Myeloproliferative neoplasms and myelodysplastic syndromes/myeloproliferative neoplasms.
This is a hetero geneous group of clonal stem disorders that is broadly divided into three groups. 9, 22 The first is the classical MPN group, which includes CML (BCR-ABL1 fusion positive), polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia not otherwise specified, mastocytosis, and MPN unclassified. The second group includes myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. The third is the MDS/MPN group, which includes chronic myelomonocytic leukemia, atypical CML (BCR-ABL1 fusion negative), juvenile myelomonocytic leukemia, and MDS/MPN unclassified. 
Chronic lymphocytic leukemia
-CLL is a mature B-cell neoplasm diagnosed by B-cell count, morphology, and flow cytometry. Cytogenetically, either peripheral blood or bone marrow can be used in CLL. G-banded chromosome analysis should be performed simultaneously with interphase FISH analysis. 31 CLL cell stimulation in culture using CpGoligonucleotides greatly improves the detection rate of clonal cytogenetic abnormalities by G-banded chromosome analysis. 6, 7 -To assign the patient into clinically relevant prognostic subgroups, the following panel of FISH probes is recommended: a. ATM (11q22.3) probe b. Centromeric probe for chromosome 12: for trisomy 12 c. 13q14.3 probe (including D13S319) d. TP53 (17p13.1) probe -FISH can also be useful for the differential diagnosis with mantle cell lymphoma (MCL), for which FISH using the IGH-CCND1 fusion probes is recommended. -In CLL, CMA analysis has proven to be very effective in detecting CNCs and cnLOH at genomic regions with established prognostic significance, and it provides a much higher resolution compared to G-banded chromosome and FISH analyses. 32, 33 Examples include 13q14 deletions, which are quite heterogeneous. 34 Moreover, clinically relevant genomic alterations in CLL involve mostly deletions and duplications, whereas most balanced translocations are relatively rare and are of unclear significance.
B-and T-cell lymphomas
-For all lymphomas, the preferred tissue is lymph node or biopsy material from a suspected lymphoid mass. 6.4.2.3 For CMA analysis, clones and subclones cannot be ascertained with certainty; however, the percentage of cells (levels of mosaicism) can be provided to give an estimate of possible clones/subclones and clonal diversity.
6.4.2.4 If a potential nonmosaic constitutional abnormality is observed, analysis of a PHA-stimulated peripheral blood sample during remission is strongly recommended to confirm that the abnormality is constitutional and not clonal.
6.4.2.5 At the time of initial diagnosis, finding a single abnormal metaphase cell, even one that is potentially significant, cannot be used as evidence of clonality unless there is strong supporting evidence of clonality for the same abnormality by either FISH or other molecular technique.
6.4.2.6 The final cytogenetic report of hematological acquired chromosomal abnormalities should contain the following information:
